Aprea Therapeutics Appoints Michael A. Kelly to Board of Directors
September 29 2020 - 7:00AM
Aprea Therapeutics Inc., (NASDAQ: APRE), a clinical-stage
biotechnology company focused on developing and commercializing
novel cancer therapeutics that reactivate mutant p53 tumor
suppressor protein, today announced the appointment of Michael A.
Kelly to its Board of Directors. Mr. Kelly will serve as a member
of the audit committee and nominating and corporate governance
committee.
Mr. Kelly brings more than 20 years of executive leadership in
the life sciences industry, including 14 years in senior leadership
roles with Amgen Inc., and is the Founder and President of Sentry
Hill Partners, LLC, a global life sciences management consulting
business. Prior to founding Sentry Hill Partners, Mr. Kelly held
multiple finance and operations positions at Amgen, most recently
serving as Senior Vice President of Global Business Services and,
in 2010 and 2014, was acting CFO. Prior to Amgen, he held senior
and executive leadership positions at Tanox, Inc. Biogen, Inc., and
Monsanto Life Sciences. Mr. Kelly holds a Bachelor of Science
degree in business administration from Florida A&M
University.
“Michael Kelly is a distinguished industry executive with
considerable experience in the management and growth of innovative
life sciences companies,” said Christian S. Schade, Chairman and
Chief Executive Officer of Aprea Therapeutics. “His deep
operational and financial expertise will be invaluable as Aprea
continues with its progress to advance our mutant p53 reactivator
oncology programs toward commercialization. It is a great pleasure
to welcome Michael to the Aprea team and our Board of
Directors.”
About Aprea Therapeutics
Aprea Therapeutics, Inc., (NASDAQ: APRE) is a biopharmaceutical
company headquartered in Boston, Massachusetts with research
facilities in Stockholm, Sweden, focused on developing and
commercializing novel cancer therapeutics that reactivate the
mutant tumor suppressor protein p53. The Company’s lead product
candidate is APR-246 (eprenetapopt), a small molecule in clinical
development for hematologic malignancies, including myelodysplastic
syndromes (MDS) and acute myeloid leukemia (AML). APR-246 has
received Breakthrough Therapy, Orphan Drug and Fast Track
designations from the FDA for MDS, and Orphan Drug designation from
the European Commission for MDS, AML and ovarian cancer. For more
information, please visit the company website at www.aprea.com.
The Company may use, and intends to use, its investor relations
website at https://ir.aprea.com/ as a means of disclosing material
nonpublic information and for complying with its disclosure
obligations under Regulation FD.
About p53 and APR-246
The p53 tumor suppressor gene is the most frequently mutated
gene in human cancer, occurring in approximately 50% of all human
tumors. These mutations are often associated with resistance to
anti-cancer drugs and poor overall survival, representing a major
unmet medical need in the treatment of cancer.
APR-246 is a small molecule that has demonstrated reactivation
of mutant and inactivated p53 protein – by restoring wild-type p53
conformation and function – and thereby induce programmed cell
death in human cancer cells. Pre-clinical anti-tumor activity has
been observed with APR-246 in a wide variety of solid and
hematological cancers, including MDS, AML, and ovarian cancer,
among others. Additionally, strong synergy has been seen with both
traditional anti-cancer agents, such as chemotherapy, as well as
newer mechanism-based anti-cancer drugs and immuno-oncology
checkpoint inhibitors. In addition to pre-clinical testing, a Phase
1/2 clinical program with APR-246 has been completed, demonstrating
a favorable safety profile and both biological and confirmed
clinical responses in hematological malignancies and solid tumors
with mutations in the TP53 gene.
A pivotal Phase 3 clinical trial of APR-246 and azacitidine for
frontline treatment of TP53 mutant MDS is ongoing. APR-246 has
received Breakthrough Therapy, Orphan Drug and Fast Track
designations from the U.S. Food and Drug Administration for MDS,
and Orphan Drug designation from the European Medicines Agency for
MDS, AML and ovarian cancer.
Forward-Looking Statements
Certain information contained in this press release includes
“forward-looking statements”, within the meaning of Section 27A of
the Securities Act of 1933, as amended, and Section 21E of the
Securities Exchange Act of 1934, as amended, related to our
clinical trials and regulatory submissions. We may, in some cases
use terms such as “predicts,” “believes,” “potential,” “continue,”
“anticipates,” “estimates,” “expects,” “plans,” “intends,” “may,”
“could,” “might,” “likely,” “will,” “should” or other words that
convey uncertainty of the future events or outcomes to identify
these forward-looking statements. Our forward-looking statements
are based on current beliefs and expectations of our management
team that involve risks, potential changes in circumstances,
assumptions, and uncertainties. Any or all of the forward-looking
statements may turn out to be wrong or be affected by inaccurate
assumptions we might make or by known or unknown risks and
uncertainties. These forward-looking statements are subject to
risks and uncertainties including risks related to the success and
timing of our clinical trials or other studies and the other risks
set forth in our filings with the U.S. Securities and Exchange
Commission, including in our Quarterly Report on Form 10-Q for the
quarter ended June 30, 2020. For all these reasons, actual results
and developments could be materially different from those expressed
in or implied by our forward-looking statements. You are cautioned
not to place undue reliance on these forward-looking statements,
which are made only as of the date of this press release. We
undertake no obligation to publicly update such forward-looking
statements to reflect subsequent events or circumstances.
Corporate Contacts:
Scott M. CoianteSr. Vice President and Chief Financial
Officer617-463-9385
Gregory A. KorbelVice President of Business
Development617-463-9385
Source: Aprea Therapeutics, Inc.
Aprea Therapeutics (NASDAQ:APRE)
Historical Stock Chart
From Jun 2024 to Jul 2024
Aprea Therapeutics (NASDAQ:APRE)
Historical Stock Chart
From Jul 2023 to Jul 2024